Edarbi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7157584 AZURITY Benzimidazole derivative and use thereof
May, 2025

(1 year, 7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920 AZURITY Benzimidazole derivative and use as a II receptor antagonist
Jan, 2025

(1 year, 3 months from now)

US9066936 AZURITY Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
Mar, 2028

(4 years from now)

Edarbi is owned by Azurity.

Edarbi contains Azilsartan Kamedoxomil.

Edarbi has a total of 3 drug patents out of which 0 drug patents have expired.

Edarbi was authorised for market use on 25 February, 2011.

Edarbi is available in tablet;oral dosage forms.

Edarbi can be used as treatment of hypertension.

The generics of Edarbi are possible to be released after 26 March, 2028.

Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient

Market Authorisation Date: 25 February, 2011

Treatment: Treatment of hypertension


How can I launch a generic of EDARBI before it's drug patent expiration?
More Information on Dosage

EDARBI family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic